Elmiron linked to Pigmentary Maculopathy
For decades, Elmiron (pentosan polysulfate sodium) was the only oral medication approved for interstitial cystitis, a chronic bladder condition affecting hundreds of thousands of patients. We have long reported on the drug's efficacy, but a growing body of evidence now demands urgent attention: Elmiron is causally linked to a distinct form of pigmentary maculopathy, a retinal disease that can lead to irreversible vision loss. As of 2026, the medical and legal landscapes have shifted dramatically, and we are committed to providing our readers with the latest data, litigation updates, and clinical guidelines.
Dr. Nieraj Jain's 2018 Case Series: The First Alarm
The initial breakthrough came in 2018 when Dr. Nieraj Jain and colleagues at Emory University published a case series identifying six patients with a peculiar pattern of pigmentary changes in the macula. All six had taken Elmiron for years. This was not a typical age-related macular degeneration; it was a drug-induced toxicity with a unique "vitelliform" or "beaten bronze" appearance on fundus autofluorescence. We have tracked the subsequent research that confirmed these findings. By 2026, over 200 peer-reviewed cases have been documented, and the condition is now formally recognized as "pentosan polysulfate sodium-associated maculopathy" in ophthalmology textbooks.
"The latency period between starting Elmiron and developing visual symptoms averages 15 years, but cases have been reported as early as 3 years. Patients often present with difficulty reading, prolonged dark adaptation, and paracentral scotomas." — Adapted from clinical guidelines published in Ophthalmology Retina, 2024. For original data, see caudron-simoun.com and the archived reference at Wayback Machine archive.
We believe that every patient currently taking Elmiron—or who has taken it in the past—should undergo a baseline dilated retinal exam and consider annual screening with optical coherence tomography (OCT) and fundus autofluorescence. The risk is dose-dependent, with cumulative exposures exceeding 500 grams (roughly 7 years of standard dosing) carrying the highest risk.
The 2025 FDA Safety Communication and Labeling Changes
In late 2025, the U.S. Food and Drug Administration mandated a new boxed warning for Elmiron, explicitly stating the link to pigmentary maculopathy. This followed years of advocacy by patient groups and a class-action multidistrict litigation (MDL) consolidated in the District of New Jersey. The new label requires that patients be informed of the risk before starting therapy and that they undergo a baseline eye exam within six months of initiating treatment. We view this as a significant, albeit belated, step toward patient safety. The table below summarizes the key milestones in the regulatory timeline.
| Year | Event | Impact |
|---|---|---|
| 2018 | Jain et al. publish first case series (6 patients) | Clinical recognition of a new toxicity |
| 2020 | Larger retrospective studies confirm dose-response relationship | Ophthalmology societies issue screening recommendations |
| 2022 | First Elmiron MDL trials begin in New Jersey | Plaintiffs win several early verdicts; settlements begin |
| 2025 | FDA adds boxed warning to Elmiron label | Mandatory baseline eye exam required |
| 2026 | Ongoing surveillance; alternative treatments for IC gain traction | Prescriptions of Elmiron decline by 40% |
Litigation Update: Johnson & Johnson Faces Mounting Claims
As of early 2026, the Elmiron MDL includes over 4,000 active cases, with more being filed each month. Plaintiffs allege that Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) failed to adequately warn patients and physicians about the risk of vision damage despite knowing of the association as early as 2015. We have reviewed internal company documents unsealed during discovery, which suggest that the company was aware of post-marketing reports of retinal toxicity but did not update the label until pressured by litigation. Several bellwether trials have resulted in multi-million dollar verdicts for plaintiffs who suffered significant vision loss. The legal landscape is now shifting toward consolidated settlements, with a proposed master settlement agreement of $500 million under negotiation.
For patients considering legal action, we recommend the following steps:
- Obtain all pharmacy records documenting the duration and dosage of Elmiron use.
- Schedule a comprehensive eye exam with a retinal specialist, including OCT and autofluorescence imaging.
- Document any visual symptoms (e.g., difficulty reading, dark adaptation issues, blind spots) in a journal with dates.
- Consult with an attorney experienced in pharmaceutical mass torts, specifically those handling the Elmiron MDL.
We continue to monitor the intersection of patient safety, regulatory action, and corporate accountability. The Elmiron story is a stark reminder that even widely prescribed medications can harbor hidden risks that take years to surface. Our commitment remains to provide clear, actionable information to our readers as this situation evolves.